X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Sun Pharma with AJANTA PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SUN PHARMA vs AJANTA PHARMA - Comparison Results

SUN PHARMA    Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SUN PHARMA AJANTA PHARMA SUN PHARMA/
AJANTA PHARMA
 
P/E (TTM) x 32.7 20.6 159.1% View Chart
P/BV x 2.7 3.5 77.2% View Chart
Dividend Yield % 0.5 1.0 46.4%  

Financials

 SUN PHARMA   AJANTA PHARMA
EQUITY SHARE DATA
    SUN PHARMA
Mar-18
AJANTA PHARMA
Mar-19
SUN PHARMA/
AJANTA PHARMA
5-Yr Chart
Click to enlarge
High Rs7011,422 49.3%   
Low Rs433898 48.3%   
Sales per share (Unadj.) Rs110.4233.5 47.3%  
Earnings per share (Unadj.) Rs11.044.0 25.0%  
Cash flow per share (Unadj.) Rs17.252.2 33.0%  
Dividends per share (Unadj.) Rs2.009.00 22.2%  
Dividend yield (eoy) %0.40.8 45.5%  
Book value per share (Unadj.) Rs158.8255.1 62.3%  
Shares outstanding (eoy) m2,399.2688.02 2,725.8%   
Bonus/Rights/Conversions -BB-  
Price / Sales ratio x5.15.0 103.4%   
Avg P/E ratio x51.626.4 195.7%  
P/CF ratio (eoy) x32.922.2 148.0%  
Price / Book Value ratio x3.64.5 78.5%  
Dividend payout %18.220.5 89.0%   
Avg Mkt Cap Rs m1,360,021102,081 1,332.3%   
No. of employees `00017.86.8 261.6%   
Total wages/salary Rs m53,6714,307 1,246.1%   
Avg. sales/employee Rs Th14,890.93,022.6 492.7%   
Avg. wages/employee Rs Th3,017.1633.4 476.3%   
Avg. net profit/employee Rs Th1,480.6569.1 260.2%   
INCOME DATA
Net Sales Rs m264,89520,554 1,288.8%  
Other income Rs m8,388211 3,978.9%   
Total revenues Rs m273,28220,765 1,316.1%   
Gross profit Rs m56,0815,664 990.1%  
Depreciation Rs m14,998721 2,080.8%   
Interest Rs m5,17612 44,618.1%   
Profit before tax Rs m44,2955,143 861.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-9,5050-   
Tax Rs m8,4521,273 663.9%   
Profit after tax Rs m26,3383,870 680.6%  
Gross profit margin %21.227.6 76.8%  
Effective tax rate %19.124.8 77.1%   
Net profit margin %9.918.8 52.8%  
BALANCE SHEET DATA
Current assets Rs m316,35911,812 2,678.2%   
Current liabilities Rs m198,6433,776 5,260.1%   
Net working cap to sales %44.439.1 113.7%  
Current ratio x1.63.1 50.9%  
Inventory Days Days9577 122.5%  
Debtors Days Days10882 132.0%  
Net fixed assets Rs m213,17814,398 1,480.6%   
Share capital Rs m2,399175 1,367.9%   
"Free" reserves Rs m378,60622,277 1,699.6%   
Net worth Rs m381,00622,452 1,697.0%   
Long term debt Rs m17,7217 268,498.5%   
Total assets Rs m643,02826,962 2,385.0%  
Interest coverage x9.6444.3 2.2%   
Debt to equity ratio x00 15,822.2%  
Sales to assets ratio x0.40.8 54.0%   
Return on assets %4.914.4 34.0%  
Return on equity %6.917.2 40.1%  
Return on capital %10.023.0 43.7%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m40,81610,682 382.1%   
Fx outflow Rs m30,1432,102 1,434.1%   
Net fx Rs m10,6738,580 124.4%   
CASH FLOW
From Operations Rs m39,0723,748 1,042.5%  
From Investments Rs m-33,708-2,228 1,512.9%  
From Financial Activity Rs m-15,393-1,475 1,043.8%  
Net Cashflow Rs m-7,35945 -16,281.2%  

Share Holding

Indian Promoters % 63.7 73.8 86.3%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 5.1 1.6 331.0%  
FIIs % 23.0 7.6 302.6%  
ADR/GDR % 0.0 0.0 -  
Free float % 8.3 17.0 48.8%  
Shareholders   133,026 20,968 634.4%  
Pledged promoter(s) holding % 0.5 4.4 12.1%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SUN PHARMA With:   PROCTER & GAMBLE HEALTH  CIPLA  TORRENT PHARMA  ALEMBIC LTD  WYETH LTD  

Compare SUN PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 234 Points Higher; Healthcare and Realty Stocks Rally(Closing)

After opening the day on a flat note, Indian share markets witnessed buying interest during closing hours and ended higher.

Related Views on News

AJANTA PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Jun 24, 2019 | Updated on Jun 24, 2019

Here's an analysis of the annual report of AJANTA PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of AJANTA PHARMA. Also includes updates on the valuation of AJANTA PHARMA.

SUN PHARMA Announces Quarterly Results (4QFY19); Net Profit Down 53.4% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, SUN PHARMA has posted a net profit of Rs 7 bn (down 53.4% YoY). Sales on the other hand came in at Rs 72 bn (up 2.7% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

AJANTA PHARMA Announces Quarterly Results (4QFY19); Net Profit Down 5.9% (Quarterly Result Update)

May 3, 2019 | Updated on May 3, 2019

For the quarter ended March 2019, AJANTA PHARMA has posted a net profit of Rs 889 m (down 5.9% YoY). Sales on the other hand came in at Rs 5 bn (down 2.9% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

SUN PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 265.5% (Quarterly Result Update)

Feb 13, 2019 | Updated on Feb 13, 2019

For the quarter ended December 2018, SUN PHARMA has posted a net profit of Rs 15 bn (up 265.5% YoY). Sales on the other hand came in at Rs 77 bn (up 16.3% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

AJANTA PHARMA Announces Quarterly Results (3QFY19); Net Profit Down 54.6% (Quarterly Result Update)

Feb 1, 2019 | Updated on Feb 1, 2019

For the quarter ended December 2018, AJANTA PHARMA has posted a net profit of Rs 669 m (down 54.6% YoY). Sales on the other hand came in at Rs 5 bn (down 17.4% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

More Views on News

Most Popular

I Believe this is the Best Stock to Buy Today(Profit Hunter)

Jul 3, 2019

The languishing small cap space is currently offering a very fertile market to pick up bargains at very attractive prices. This is a perfect opportunity ripe for the picking.

These 3 Smallcap Stocks are Set to Make the Most of Smallcap Rebound(Profit Hunter)

Jul 9, 2019

As the sense of normalcy returns to the markets, the rebound in the quality smallcaps could be huge.

2 Stocks from Super Investor Sanjay Bakshi's Portfolio You Can Bet On...(The 5 Minute Wrapup)

Jul 12, 2019

Despite the current fear prevailing in the markets, both these stocks have the potential to deliver in 4-5 years.

After Disappointing Budget, Here's a Document that Concerns Largecap and Smallcap Investors(The 5 Minute Wrapup)

Jul 8, 2019

A new 'definition' of the stock universe that triggered the smallcap sell-off is back with the latest list...

Union Budget 2019-2020: More Style Over Substance(The 5 Minute Wrapup)

Jul 5, 2019

Did the Union Budget announce measures to stimulate the economy and bolster corporate earnings growth?

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

SUN PHARMA SHARE PRICE


Jul 16, 2019 (Close)

TRACK SUN PHARMA

  • Track your investment in SUN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SUN PHARMA 8-QTR ANALYSIS

COMPARE SUN PHARMA WITH

MARKET STATS